Filing Details

Accession Number:
0001193805-15-002110
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-12-18 19:43:49
Reporting Period:
2015-12-16
Filing Date:
2015-12-18
Accepted Time:
2015-12-18 19:43:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1347178 Vanda Pharmaceuticals Inc. VNDA Pharmaceutical Preparations (2834) 030491827
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1009258 Deerfield Management Co 780 Third Avenue, 37Th Floor
New York NY 10017
No No Yes Yes
1010823 L.p. Mgmt Deerfield 780 Third Avenue, 37Th Floor
New York NY 10017
No No Yes Yes
1301041 Deerfield Partners, Lp 780 Third Avenue, 37Th Floor
New York NY 10017
No No Yes Yes
1352546 E James Flynn 780 Third Avenue, 37Th Floor
New York NY 10017
No No Yes Yes
1354395 Deerfield Special Situations Fund, L.p. 780 3Rd Avenue
37Th Floor
New York NY 10017
No No Yes Yes
1565089 Deerfield International Master Fund, L.p. 780 3Rd Avenue
37Th Floor
New York NY 10017
No No Yes Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-12-16 3,490 $8.97 2,152,952 No 4 P Indirect Through Deerfield Partners, L.P.
Common Stock Acquisiton 2015-12-16 4,441 $8.97 2,740,122 No 4 P Indirect Through Deerfield International Master Fund, L.P.
Common Stock Acquisiton 2015-12-16 3,239 $8.97 1,103,617 No 4 P Indirect Through Deerfield Special Situations Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect Through Deerfield Partners, L.P.
No 4 P Indirect Through Deerfield International Master Fund, L.P.
No 4 P Indirect Through Deerfield Special Situations Fund, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.83 to $9.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) of this Form 4.
  2. This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P. (collectively, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
  3. In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.